← Back to Search

Monoclonal Antibodies

Cohort 1: Camoteskimab 7 mg/kg for Still's Disease

Phase 1
Waitlist Available
Led By Isabelle Peene, MD, PhD
Research Sponsored by Cerecor Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 4 and week 12
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new medication called Camoteskimab to see if it is safe and well-tolerated in people with Still's Disease.

Eligible Conditions
  • Still's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 4 and week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 4 and week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change from Baseline in the Patient Global Assessment of Disease Activity
Change from Baseline in the Physician Global Assessment of Disease Activity
Proportion of subjects who achieved absence of fever

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort 2: Camoteskimab Dose escalation/reductionExperimental Treatment1 Intervention
Cohort 2 dose will be determined based on a review of Cohort 1 data. 6 participants will be administered camoteskimab at the determined dose at Baseline, Week 4, and Week 8.
Group II: Cohort 1: Camoteskimab 7 mg/kgExperimental Treatment1 Intervention
6 participants will be administered camoteskimab at a dose of 7 mg/kg (500 mg maximum) at Baseline, Week 4, and Week 8.

Find a Location

Who is running the clinical trial?

Cerecor IncLead Sponsor
8 Previous Clinical Trials
1,907 Total Patients Enrolled
Avalo Therapeutics, Inc.Lead Sponsor
12 Previous Clinical Trials
2,101 Total Patients Enrolled
Apollo Therapeutics LtdLead Sponsor
3 Previous Clinical Trials
272 Total Patients Enrolled
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top